US · Healthcare · Biotechnology
EPS came in at -1.90 against a street estimate of -1.83 — a miss of 3.8%.
Analysts rate Quoin Pharmaceuticals Ltd DRC a strong buy (7 buy, 0 hold, 0 sell out of 7) with an average price target of $20.38.
| Fund | Stake |
|---|---|
| Dauntless Investment Group, LLC | 4.47% |
| Ikarian Capital, LLC | 4.40% |
| Stonepine Capital Management Llc | 4.15% |
| Millennium Management LLC | 2.34% |
| SummitTX Capital, L.P | 2.09% |
| Woodline Partners LP | 1.59% |
| Aberdeen Group PLC | 1.56% |
| Soleus Capital Management, L.P. | 1.51% |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Quoin Pharmaceuticals Ltd DRC — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-11-07.